Comprehensive Medicinal Chemistry II (Volume 2): Strategy and Drug Research

Strategy and project management is very important in the pharmaceutical and biotechnology industries as it can take a decade and over a billion dollars to develop a successful drug. This comprehensive volume presents academic, industry and other complementary viewpoints on the drug research process with many illustrative examples, anecdotes and representative case studies. Experts evaluate the strengths and weaknesses of old and new methods, the crossroads of tactics and strategy and market forces. Project management chapters highlight decisions that must be made along the drug discovery pathway and investigate outsourcing, licensing, innovation and managing scientists. The volume concludes with some case studies so that readers can examine practical applications of strategy and project management applied to real life examples.

* valuable content available from May 2009 as an individual volume
* separate volumes will appeal to a wider chemistry, biochemistry and medicinal audience
* priced for individual researcher as well as library purchase

Walter Moos has been an adjunct Professor of Pharmaceutical Chemistry at the University of California San Francisco (UCSF) since 1992. In parallel, he has been Managing Director of Pandect Bioventures, which he co-founded in 2018. At ShangPharma Innovation, starting in 2016 as an advisor, then as CEO, and most recently as emeritus Chairman, he led development of the group's innovation ecosystem. He is past President of Biosciences at the independent nonprofit Stanford Research Institute (SRI International), where he spent more than a decade, until 2016. Moos also managed corporate IT Services at SRI. Earlier he was Chairman/CEO of MitoKor (Micrologics/Migenix) and a VP at Chiron (Novartis) and at Warner-Lambert/Parke-Davis (Pfizer). He and his teams have made significant contributions to all R&D phases from early-stage research on chemical and biological therapeutics and diagnostics to marketed pharmaceutical products. They have done this with the support of big pharma, foundations, government grants and contracts, and venture capital. Moos has served on more than 20 business and scientific boards, public and private, non-profit and for-profit, including Alnis, Amunix (Sanofi), Anterion, Aprinoia, Axiom (Sequenom), the Biotechnology Industry (Innovation) Organization (BIO), Circle, the Critical Path Institute, Global Blood (Pfizer), Keystone Symposia, Mimotopes (Fisher/Thermo), MitoKor (Micrologics/Migenix), Oncologic (Aduro/Chinook), Onyx (Amgen), Rigel, ShangPharma Innovation, Valitor, and the Virginia University Research Partnership. He has advised companies on several continents and served as a committee member for academic, government, and investor groups, including the US National Academy of Sciences. He has co-founded several scientific journals, co-authored or edited multiple books, and has around 200 patents and publications. Moos has held faculty positions at several major universities and received PhD and AB degrees in chemistry from UC Berkeley and Harvard, respectively.